Exploratory/Developmental Grant for Complementary and Alternative Medicine (CAM) Studies using Cells, Tissues, and Animal Models of Disease (R21) | Apply Online

Opportunity Summary:

The Exploratory/Developmental Grant for Complementary and Alternative Medicine (CAM) Studies using Cells, Tissues, and Animal Models of Disease (R21) is a National Institutes of Health (NIH) funding opportunity (Funding Opportunity Number PA-08-185) designed to support early-stage, mechanism-focused research in complementary and alternative medicine. The main goal is to encourage basic and preclinical studies that help explain how a particular CAM modality works at a biological level. Rather than focusing on large clinical trials, the emphasis is on controlled experimental systems such as cells and cell lines, tissues, cadavers, and animal models of disease, where investigators can probe pathways, targets, and physiological effects in a way that is often not possible in human studies. The opportunity is sponsored by the National Center for Complementary and Alternative Medicine (NCCAM, now known as NCCIH), with involvement from the National Cancer Institute (NCI) and the NIH Office of Dietary Supplements (ODS), signaling interest in CAM approaches that may intersect with cancer biology, prevention, detection, diagnosis, treatment, and dietary supplement science.

This announcement uses the NIH R21 mechanism, which is meant for exploratory and developmental projects. In practice, that means the program is well-suited for new ideas, early proof-of-concept work, or the kind of preliminary mechanistic evidence that can later justify a larger, more definitive project. The FOA explicitly notes that it runs in parallel with a separate, scientifically identical opportunity that uses the R01 mechanism (PA-07-007). That parallel structure is a common NIH approach: investigators with a more mature research plan and stronger preliminary data might target the R01, while those developing a newer line of inquiry or testing a high-impact hypothesis with limited preliminary evidence may fit better under the R21.

The scientific scope centers on understanding mechanisms of action for CAM modalities using non-human or preclinical systems. Applicants are expected to use experimental models to clarify how an intervention, practice, or product influences biological processes relevant to disease or health. Because this FOA includes cells, tissues, cadavers, and animal models, it implicitly supports a wide range of mechanistic approaches, such as molecular signaling studies, pharmacologic or biochemical assays, physiology experiments, and pathology-based outcomes, depending on the CAM modality and disease model selected. The involvement of NCI and the listing of multiple cancer-related CFDA numbers indicate that cancer-relevant CAM mechanistic research is within scope, including studies tied to cancer cause and prevention, detection and diagnosis, treatment, and cancer biology, as well as broader complementary and integrative health research and training.

Funding details reflect the flexible, project-dependent nature of R21 awards. The announcement states that award size and duration will vary based on what is proposed, and that the number of awards and total dollars ultimately depend on the volume and quality of applications received, as well as their proposed budgets and project periods. The posted award ceiling listed in the source data is $200,000, and the opportunity does not require cost sharing or matching funds, which can make it more accessible to organizations that may not have discretionary resources to contribute.

Eligibility is broad and includes many different types of institutions and organizations. Eligible applicants include public and state-controlled institutions of higher education, private institutions of higher education, nonprofit organizations (including those with and without 501(c)(3) status), for-profit organizations other than small businesses, small businesses, and multiple levels of government (state, county, city/township, special district, and independent school districts). The eligibility language also extends to public housing authorities/Indian housing authorities, federally recognized Native American tribal governments and other tribal organizations, and a variety of mission-focused and capacity-building institution types such as Historically Black Colleges and Universities (HBCUs), Hispanic-Serving Institutions, Alaska Native and Native Hawaiian Serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), and faith-based or community-based organizations. Notably, the FOA also allows non-domestic (non-U.S.) entities (foreign organizations), regional organizations, eligible federal agencies, and U.S. territories or possessions, indicating that NIH was open to receiving mechanistic CAM research applications from a global and diverse set of applicants, provided other NIH requirements were met.

Key administrative details in the source data show the opportunity was posted on June 26, 2008, with dates in the record indicating creation on October 16, 2009, and an archive date of February 7, 2010. The source fields list an original closing date of September 7, 2011, but a current closing date of January 7, 2010, which suggests the listing may reflect an updated or archived record rather than a single continuous open period. Applicants were directed to the full FOA text through the NIH Grants Guide link, and NIH provided technical contact support through the NIH Office of Extramural Research (OER) webmaster for access or linking issues.

In plain terms, this R21 opportunity was built to help researchers generate strong mechanistic evidence about how CAM interventions affect biological systems relevant to disease, using tightly controlled preclinical models. It is positioned as a stepping-stone funding mechanism for innovative or emerging ideas, and it is open to a wide range of applicant organizations, including academic institutions, nonprofits, businesses, government entities, tribal organizations, and foreign institutions, with particular relevance for CAM research that intersects with cancer and dietary supplement science.

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Education Health

Next opportunity: Medications Development for Polydrug Addiction Treatment (R01)

Previous opportunity: Collaborations with National Centers for Biomedical Computing (R01)

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for PA 08 185

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (PA 08 185) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "PA 08 185", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.